ArticlePloS one2026
Prognostic value of melatonin-related signature genes in lung adenocarcinoma.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeLung adenocarcinoma (LUAD), the most prevalent lung cancer subtype, has witnessed a dramatic upsurge in frequency over the past 20 years. This study intended to construct a predictive risk model and analyze melatonin (ME)-associated genes in LUAD.
methodsDifferentially expressed genes (DEGs) were found by using DESeq2 to analyze the TCGA-LUAD dataset. ME-DEGs were discovered near the junction, and ME critical module genes were identified by WGCNA. To build a risk model, model genes from ME-DEGs were chosen using univariate and multivariate Cox analysis. The samples were categorized as either low-risk or high-risk. The model was verified using the GSE31210 dataset. Gene expression was confirmed by RT-qPCR, immunological studies were performed, and a nomogram was developed.
resultsThe 98 ME-DEGs were obtained by combining 1,052 ME key module genes with 5,449 LUAD-DEGs. Eight model genes were selected using univariate and multivariate cox regression analyses. The risk model, which was constructed using model genes, showed good predictive performance in both the TCGA-LUAD and GSE31210 datasets. Additionally, the nomogram's superior predictive accuracy for LUAD was confirmed by calibration and receiver operating characteristic (ROC) curves. Additionally, the results of immune analysis showed that ALG3 and FRY had significant relationships with immune cells and immune checkpoints, and that E2F1 had a significant negative association with FRY.
conclusionWe developed and validated a novel ME-related prognostic model for LUAD. This algorithm may be able to predict patient outcomes and provide recommendations for tailored immunotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.